PubMed Health⌕ Search

Biomedical subjects

O S Sardaş

Publications and source records attributed to O S Sardaş.

7 recordsLinked to original sources
PubMed1994

Sister chromatid exchange studies for monitoring DNA damage in lymphocytes of malignant lymphoma patients under cytostatic therapy.

Sister chromatid exchange (SCE) frequencies were studied in lymphocytes from 45 patients with malignant lymphoma. Fifteen patients were untreated when studied. The mean SCE frequency for these patients was 8.70 +/- 0.99 per mitosis. The mean score for 35 controls was 4.37 +/- 1.19. SCE mean scores were significantly higher in the untreated patients than in the controls (p < 0.001). Nine patients were treated with radiotherapy alone. The mean SCE frequency (6.80 +/- 0.87) they demonstrated was significantly lower (p < 0.01) than that found in untreated patients. Twelve patients received cyclophosphamide 1 month before the study was started. They demonstrated a mean SCE frequency (12.00 +/- 1.31) significantly higher (p < 0.05) than that found in patients who had received regimens that did not contain cyclophosphamide (9.72 +/- 1.32). From these findings we suggest that untreated patients with malignant lymphoma have elevated SCE frequencies, which may be further increased by chemotherapeutic agents.

Adult↗
PubMed1992

P-glycoprotein expression in refractory hematological neoplasms and circumvention of resistance with verapamil or cyclosporine A containing protocols.

Either p-glycoprotein (pgp) or the encoding gene mdr1 expression has been reported to be correlated with multidrug resistance and poor treatment response. To investigate the incidence of pgp in refractory hematological neoplasms we analyzed malignant cells from 40 patients by an immunoperoxidase method using the monoclonal antibody C219. Pgp was positive in 75% of acute nonlymphoblastic leukemia (ANLL) and 50% of acute lymphoblastic leukemia (ALL). Pgp positivity was similarly distributed in both Tdt (-) and (+) ANLLs (64% versus 100%). Addition of Verapamil (VRP) (12 patients) or Cyclosporine A (CsA) (7 patients) to the previous chemotherapy protocol resulted in complete response in 7 (58%) and 3 (43%) of the patients respectively. Partial response was observed in one patient who received CsA. Both chemosensitizers were tolerated well with few reversible side effects. The preliminary results of this study have been presented in the 15th International Cancer Congress, August 1990 Hamburg, Germany.

ATP Binding Cassette Transporter, Subfamily B, Mem↗